Eli Lilly CDR (CAD Hedged)

Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a first-in-class monoclonal antibody targeting fibrin-mediated neuroinflammation in Alzheimer's disease.

Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.

BioChaperone Lispro (THDB0206) demonstrated non-inferior HbA1c reduction compared to Humalog in a Phase 3 trial of 1,040 Chinese adults with Type 2 diabetes.

Gate Bioscience announced a collaboration and license agreement with Eli Lilly to discover and develop molecular gate therapeutics, a new class of small molecule drugs that eliminate disease-causing proteins at their source.

Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.

IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.

Eli Lilly's FORAGER-1 Phase 1 study is evaluating LOXO-435 (LY3866288) as both monotherapy and combination treatment for locally advanced or metastatic solid tumors with FGFR3 gene alterations.

Livzon Pharmaceutical's LZM012, the first domestic dual-target IL-17A/F monoclonal antibody, achieved superior efficacy compared to Secukinumab in a Phase III trial for moderate to severe plaque psoriasis.

Omega Funds successfully closed its eighth fund with $647 million in capital commitments, exceeding its $600 million target despite challenging fundraising conditions.

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.